Novartis announced financial results and new regulatory approvals
In the first nine months of 2026, Novartis reported a net income of $7.6 billion on total sales of $42.0 billion. In October, the company also announced approvals for the drugs Rhapsido, Pluvicto, and Fabhalta.
Key points
- Novartis revenue for the first nine months of 2026 was $42.0 billion, up 2% compared to the same period last year.
- Clinical trials showed mixed results.
- Novartis completed the acquisition of Myricx Bio for $1.1 billion to expand its oncology portfolio.
Financial results and regulatory milestones.
Novartis revenue for the first nine months of 2026 was $42.0 billion, up 2% compared to the same period last year. The company's operating income reached $10.8 billion, net income was $7.6 billion, and core operating income was $16.9 billion.
In October, Novartis reported a series of regulatory approvals. Specifically, Rhapsido received FDA approval to treat dermographism symptoms. Pluvicto, in combination with androgen receptor pathway inhibitors, was approved by the FDA and NMPA to treat metastatic prostate cancer, while Fabhalta received approval in Japan and traditional FDA approval to treat IgA nephropathy.
Clinical trial status.
Clinical trials showed mixed results. Remibrutinib met its primary endpoint in a multiple sclerosis study, but the trial for generalized myasthenia gravis was discontinued due to futility. Additionally, the drugs del-desiran and pelacarsen failed to meet their primary endpoints in key trial phases.
Capital transactions and deals.
Novartis completed the acquisition of Myricx Bio for $1.1 billion to expand its oncology portfolio. The company also issued $12.9 billion in bonds, with the proceeds partially used to repay a bridge loan previously obtained to fund the acquisition of Avidity Biosciences.
Victor Bulto Carulla, an officer of the company, filed a notice of a proposed sale of 6,000 American Depositary Shares with an estimated value of $933,180 as of October 28, 2026.
Upcoming events.
Investors should look forward to the "Meet Novartis Management 2026" event, which will take place on November 18-19, 2026, in London. Fourth quarter and full-year 2026 reports are scheduled for February 3, 2027, and the annual general meeting of shareholders for March 5, 2027.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Novartis
A notification in your browser or on your phone when we publish about Novartis. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
